Evolving Our Partnership: The CSER2 Centralized Support Coordinating Center

发展我们的合作伙伴关系：CSER2 集中支持协调中心

• 批准号: 10360348
• 负责人: Stephanie Malia Fullerton
• 金额: $ 92.52万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10360348
• 关键词: Clinical; Clinical effectiveness; Effectiveness; Family member; Genomic medicine; Genomics; Goals; Individual; Logistics; Outcome; Patients; Phase; Physicians; Population; Recommendation; Research; Site; Time; Work; clinical sequencing; evidence base; experience; success; synergism

Abstract The overall goal in this competitive renewal proposal for the Clinical Sequencing Exploratory Research (CSER) Consortium coordinating center (CC) is to enhance the effectiveness of the next CSER phase (CSER2) by assuring the effective coordination and logistic support needed to propel cross-consortium efforts and to identify new synergies that increase the scientific value of the individual projects. CSER2 will continue to generate the evidence base required for clinical genomic medicine, expanding its reach into non-academic centers and enhancing the diversity of the patient groups. It will provide timely, pragmatic information about best practices for genomic medicine that permit optimal provide useful and accessible recommendations for physicians, patients, family members, and policymakers. In approaching this task, we will leverage our considerable experience as the existing CSER CC and as partners in many other genomics consortia, including expertise in diverse and non-academic populations to facilitate the work of CSER2. In the current cycle of CSER (CSER1) the UW CC has made numerous significant contributions to the important work of CSER, as outlined in the progress section. Our success is underscored by the fact that the PIs at every CSER1 UO1 site support UW continuing as the CSER2 CC.

抽象的 临床测序探索性研究的竞争更新建议的总体目标 （CSER）财团协调中心（CC）是为了提高下一个CSER阶段的有效性 （CSER2）通过确保推动跨委托区所需的有效协调和后勤支持 努力并确定增加各个项目科学价值的新协同作用。 CSER2 将继续产生临床基因组医学所需的证据基础，扩大其影响力 进入非学术中心并增强患者群体的多样性。它将及时提供 有关允许最佳基因组医学最佳实践的务实信息，可提供有用和 针对医师，患者，家庭成员和决策者的可访问建议。接近 这项任务，我们将利用我们作为现有CSER CC的丰富经验以及作为合作伙伴 许多其他基因组学联盟，包括各种和非学术人群的专业知识，以促进 CSER2的工作。在CSER（CSER1）的当前周期中，UW CC已成为许多重要的 如《进度》部分概述了CSER重要工作的贡献。我们的成功是 对每个CSER1 UO1站点的PI都支持UW继续以CSER2 cc的速度支持的事实强调了这一事实。